3rd Precision Medicine in Inflammatory Bowel Disease Summit | May 13-15, 2025

Memo

Welcome to the 3rd Precision Medicine in Inflammatory Bowel Disease SummitDeliver Safe and Effective Precision Therapies to Every IBD PatientWith fierce competition in clinical trials for Chron's Disease and Ulcerative Colitis following a year of exceptional progress in IBD drug development, biopharma must now push the boundaries of efficacy and distinguish their therapies amongst the market.Driving innovation in IBD treatment, the 3rd Precision Medicine in Inflammatory Bowel Disease Summit returns to Boston in May, uniting 80+ biopharma, diagnostics providers, and academic leaders to explore breakthrough advancements in AI, biomarker development, patient stratification, and novel therapies.Featuring a dedicated Technology Innovation in IBD Focus Day, expert-led discussions, and exclusive networking opportunities, this meeting offers unmatched opportunities to connect with decision makers, discover transformative solutions, and shape the future of precision medicine in IBD. Don't miss your chance to lead progress in this rapidly evolving field!URLs:Brochure: https://go.evvnt.com/2873002-0?pid=5569Tickets: https://go.evvnt.com/2873002-2?pid=5569Date and Time: On Tuesday May 13, 2025 at 8:00 am to Thursday May 15, 2025 at 3:40 pmVenue details: Revere Hotel Boston Common, 200 Stuart Street, Boston, Massachusetts, 02116, United StatesPrices:Conference + Focus Day (3 Day Pass) - Drug Developer Pricing: USD 4197.00,Conference Only - Drug Developer Pricing: USD 2999.00,Conference + Focus Day (3 Day Pass) - Academic Pricing: USD 3597.00,Conference Only - Academic Pricing: USD 2599.00,Conference + Focus Day (3 Day Pass) - Solution Provider Pricing: USD 5097.00,Conference Only - Solution Provider Pricing: USD 3699.00Speakers: Ben Kostiuk Director, Life Science Partnerships, Crohn's and Colitis Foundation of America, Bryan Linggi, Senior Director, Translational Research, AnaptysBio, Eileen Crowley, Assistant Professor and Director, Pediatric IBD Centre, Childrens Hospital Western Ontario, Gerard Honig, Associate Director, Biomarker Research, Otsuka, Ilan Wapinski, Head, Biomarkers and Patient Stratification, Sanofi, Irene Modesto, Vice President, Medical Affairs, Pfizer, Joanne Tan, Senior Vice President and Head, Research and Development, Parvus Therapeutics, Joerg Heyer, Head of Translational Science and Medicine, Palisade Bio, Joshua Friedman, Senior Vice President, Clinical Development, Spyre Therapeutics, Josselin Caradec, Head of Biology, ThirtyFiveBio, Judy Chou, President and Chief Executive Officer, AltruBio, Katia Karalis, Executive Director, RGC, Regeneron Pharmaceuticals, Katja Conrath, Chief Scientific Officer, MRM Health, Laurence Cheng, Executive Director and Precision Medicine Therapeutic Area Head, Inflammation and Rare Disease, Amgen, Marc Levesque, Vice President, Immunology Discovery and MRL, Merck and Co, Mark Osterman, Vice President, Disease Area Head of Gastroenterology, Bristol Myers Squibb, Mohamed Hassanein, Director, Translational Medicine, Pfizer, Neil Humphryes-Kirilov, Associate Director, Human Genomics, C4X Discovery, Paul Kayne, Vice President, Biological Sciences, Palatin Technologies, Pratik Panchal, Head, Translational Medicine, Takeda Pharmaceutical, Sarah Grant, Vice President and Head, Early Clinical Development, Respiratory and Immunology, AstraZeneca, Scott Thacher, Chief Executive Officer and Founder, Orphagen Pharmaceuticals, Stefan Schreiber, Professor of Medicine, Director Department of Internal Medicine, University Hospital Schleswig-Holstein (UKSH), Kiel University, Steven Levitte, Medical Director - Product Development, Gastroenterology Hepatology and Metabolism, Genentech, Vinayagam Arunachalam, Director and Head, Computational and Systems Biology, Early Clinical Development, GI2-TAU, Takeda Pharmaceutical